<DOC>
	<DOCNO>NCT00782275</DOCNO>
	<brief_summary>The purpose research study find effect ( good bad ) study treatment participant cancer . Temsirolimus approve Food Drug Administration ( FDA ) treatment renal cell carcinoma . Avastin approve FDA type cancer renal cell carcinoma .</brief_summary>
	<brief_title>Avastin Temsirolimus Following Tyrosine Kinase Inhibitor Failure Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>- Participants receive avastin day 1 15 28-day treatment cycle . They receive temsirolimus day 1 , 8 , 15 22 cycle . - During treatment cycle , participant physical exam , blood test , urine test . An assessment tumor CT ( Computerized Tomography ) scan perform every 8 week . - It anticipate participant research study 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm renal cell carcinoma either primary metastatic lesion . Nonclear histology allow . Disease progression VEGFtargeted tyrosine kinase inhibitor recent therapy experience intolerable toxicity require discontinuation . Only one prior VEGFtargeted tyrosine kinase inhibitor . Must VEGFtargeted tyrosine kinase inhibitor 2 week great . One measurable lesion curable standard radiation therapy surgery . The enrol site must agree obtain paraffinembedded tumor block least 10 unstained , paraffinembedded slide submission correlative study . 18 year age old ECOG Performance Status 0 1 Baseline laboratory value outline protocol Life expectancy great 3 month No prior malignancy diagnose within past three year , superficial basal cell superficial squamous cell , carcinoma situ cervix . Known CNS disease , except treat brain metastasis Previously treat avastin mTOR inhibitor Other VEFGtargeted TKI , patient may prior immunotherapy chemotherapy stage IV disease History allergic reaction Chinese hamster ovary cell product , recombinant antibody , compound similar chemical biologic composition avastin temsirolimus History bleeding diathesis coagulopathy . Therapeutic anticoagulant allow Patients clinically significant cardiovascular disease Patients receive enzymeinducing antiepileptic drug CYP3A4 inducer rifampin St. John 's wort No serious nonhealing wound , ulcer bone fracture No uncontrolled intercurrent illness include , limited , ongoing active infection require parental antibiotic psychiatric illness/social situation would limit compliance study requirement HIVpositive receive combination antiretroviral therapy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior enrollment study History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Known hypersensitivity component avastin temsirolimus Life expectancy le 12 week History hemoptysis within 1 month prior day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>RCC</keyword>
	<keyword>avastin</keyword>
	<keyword>temsirolimus</keyword>
</DOC>